Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21814436 | 0.77 | ACHE (0.38) | MAOAMAOBMAPTERBB2MEN1 | |
| SCHEMBL21814428 | 0.73 | ACHE (0.40) | MAPTERBB2MEN1ALDH1A1HPGD | |
| SCHEMBL15630516 | 0.72 | ALDH1A1 (0.36) | MAOAMAOBMAPTERBB2MEN1 | |
| SCHEMBL21814456 | 0.71 | ALDH1A1 (0.51) | MAPTERBB2ALDH1A1TDP1ACHE | |
| SCHEMBL10806369 | 0.69 | MAPT (0.42) | MAPTERBB2MEN1ALDH1A1HPGD | |
| SCHEMBL21814608 | 0.69 | ACHE (0.49) | MAPTMEN1ALDH1A1KMT2AACHE | |
| SCHEMBL7606757 | 0.69 | ERBB2 (0.41) | MAOAMAOBMAPTERBB2MEN1 | |
| SCHEMBL21814610 | 0.68 | ACHE (0.51) | MAPTMEN1ALDH1A1KMT2AACHE | |
| SCHEMBL21814446 | 0.68 | ACHE (0.51) | MAPTMEN1ALDH1A1KMT2AACHE | |
| SCHEMBL21818683 | 0.68 | ACHE (0.51) | MAPTMEN1ALDH1A1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041849-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2024-02-08 | — | — | US | disclosed |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3829560-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | Musc Foundation for Research Development (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-112770735-A | Compounds for the treatment of neurological or mitochondrial diseases | MUSC研究发展基金会 | 2021-05-07 | — | — | CN | disclosed |
| WO-2020028222-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041849-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MT-ND2, MT-ND1, NLN | MAOA 1603/4885MAOB 1073/4885MAPT 294/4885 |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MT-ND2, MT-ND1, NLN | MAOA 1603/4885MAOB 1073/4885MAPT 294/4885 |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MT-ND2, MT-ND1, NLN | MAOA 1603/4885MAOB 1073/4885MAPT 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.